JP2017512825A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512825A5 JP2017512825A5 JP2016561611A JP2016561611A JP2017512825A5 JP 2017512825 A5 JP2017512825 A5 JP 2017512825A5 JP 2016561611 A JP2016561611 A JP 2016561611A JP 2016561611 A JP2016561611 A JP 2016561611A JP 2017512825 A5 JP2017512825 A5 JP 2017512825A5
- Authority
- JP
- Japan
- Prior art keywords
- agent according
- antibody
- nme7
- seq
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 101001128732 Homo sapiens Nucleoside diphosphate kinase 7 Proteins 0.000 claims 3
- 102100032115 Nucleoside diphosphate kinase 7 Human genes 0.000 claims 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461976390P | 2014-04-07 | 2014-04-07 | |
| US61/976,390 | 2014-04-07 | ||
| USPCT/US2014/050773 | 2014-08-12 | ||
| PCT/US2014/050773 WO2015023694A2 (en) | 2013-08-12 | 2014-08-12 | Method for enhancing tumor growth |
| USPCT/US2014/061821 | 2014-10-22 | ||
| USPCT/US2014/061821 | 2014-10-22 | ||
| US201562114526P | 2015-02-10 | 2015-02-10 | |
| US62/114,526 | 2015-02-10 | ||
| US201562127746P | 2015-03-03 | 2015-03-03 | |
| US62/127,746 | 2015-03-03 | ||
| PCT/US2015/024764 WO2015157322A2 (en) | 2014-04-07 | 2015-04-07 | Anti-nme antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018165618A Division JP6646118B2 (ja) | 2014-04-07 | 2018-09-05 | 抗ｎｍｅ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017512825A JP2017512825A (ja) | 2017-05-25 |
| JP2017512825A5 true JP2017512825A5 (enExample) | 2017-07-06 |
| JP6401292B2 JP6401292B2 (ja) | 2018-10-10 |
Family
ID=54288530
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561611A Active JP6401292B2 (ja) | 2014-04-07 | 2015-04-07 | 抗ｎｍｅ抗体 |
| JP2018165618A Active JP6646118B2 (ja) | 2014-04-07 | 2018-09-05 | 抗ｎｍｅ抗体 |
| JP2020001446A Active JP7042854B2 (ja) | 2014-04-07 | 2020-01-08 | 抗ｎｍｅ抗体 |
| JP2022040438A Pending JP2022095648A (ja) | 2014-04-07 | 2022-03-15 | 抗ｎｍｅ抗体 |
| JP2024032381A Pending JP2024084747A (ja) | 2014-04-07 | 2024-03-04 | 抗ｎｍｅ抗体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018165618A Active JP6646118B2 (ja) | 2014-04-07 | 2018-09-05 | 抗ｎｍｅ抗体 |
| JP2020001446A Active JP7042854B2 (ja) | 2014-04-07 | 2020-01-08 | 抗ｎｍｅ抗体 |
| JP2022040438A Pending JP2022095648A (ja) | 2014-04-07 | 2022-03-15 | 抗ｎｍｅ抗体 |
| JP2024032381A Pending JP2024084747A (ja) | 2014-04-07 | 2024-03-04 | 抗ｎｍｅ抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20170204196A1 (enExample) |
| EP (2) | EP3129476B1 (enExample) |
| JP (5) | JP6401292B2 (enExample) |
| KR (2) | KR102294483B1 (enExample) |
| CN (1) | CN106414726A (enExample) |
| AU (1) | AU2015243948B2 (enExample) |
| CA (1) | CA2945162A1 (enExample) |
| IL (2) | IL248220A0 (enExample) |
| SG (2) | SG11201608389RA (enExample) |
| TW (1) | TWI746420B (enExample) |
| WO (1) | WO2015157322A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3129476B1 (en) | 2014-04-07 | 2022-01-05 | Minerva Biotechnologies Corporation | Anti-nme antibody |
| JP6895890B2 (ja) | 2015-02-10 | 2021-06-30 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗ｍｕｃ１＊ 抗体 |
| EP3525804A4 (en) * | 2016-10-11 | 2020-09-09 | Minerva Biotechnologies Corporation | HUMANIZED ANTI-MUC1 * ANTIBODIES AND USE OF THE CLIVING ENZYME |
| IL302144A (en) | 2017-03-29 | 2023-06-01 | Minerva Biotechnologies Corp | Agents for stem cell differentiation and cancer treatment |
| CN113727602B (zh) * | 2019-02-04 | 2023-10-03 | 米纳瓦生物技术公司 | 抗nme抗体及治疗癌症或癌症转移的方法 |
| CA3181655A1 (en) * | 2020-06-08 | 2021-12-16 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| KR20230028796A (ko) * | 2020-06-26 | 2023-03-02 | 미네르바 바이오테크놀로지 코포레이션 | 항-nme 항체 및 암 또는 암 전이의 치료 방법 |
| AU2023253692A1 (en) | 2022-04-12 | 2024-11-14 | Minerva Biotechnologies Corporation | Anti-variable muc1* antibodies and uses thereof |
| US20240261406A1 (en) | 2023-02-02 | 2024-08-08 | Minerva Biotechnologies Corporation | Chimeric antigen receptor compositions and methods for treating muc1* diseases |
| WO2025049494A1 (en) | 2023-08-29 | 2025-03-06 | Minerva Biotechnologies Corporation | Bacterial nme7 orthologs and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5631271A (en) | 1986-11-29 | 1997-05-20 | Serfontein; Willem J. | Methods and preparations for the treatment and prophylaxis of metabolic disturbances |
| US5874285A (en) * | 1996-09-13 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding a novel human nm23-like protein |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| CA2384713A1 (en) | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| AUPR011700A0 (en) | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
| US20050163784A1 (en) | 2002-06-17 | 2005-07-28 | Valentijn Linda J. | Novel cancer therapies |
| JP2006502110A (ja) * | 2002-07-03 | 2006-01-19 | イミュノジェン・インコーポレーテッド | 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用 |
| AU2003299643A1 (en) * | 2002-12-04 | 2004-06-23 | Diadexus, Inc. | Compositions, splice variants and methods relating to colon specific genes and proteins |
| WO2006133420A2 (en) | 2005-06-08 | 2006-12-14 | Millennium Pharmaceuticals, Inc. | Treatment of patients with cancer therapy |
| WO2007072221A2 (en) | 2005-11-10 | 2007-06-28 | Aurelium Biopharma Inc. | Surface marker-directed cancer therapeutics |
| AU2008265928A1 (en) | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Synergistic treatment of cells that express EphA2 and ErbB2 |
| EP2334703B1 (en) | 2008-09-17 | 2015-07-08 | Innate Pharma | Compositions and methods for detecting tlr3 |
| CN102239182B (zh) | 2008-10-06 | 2014-07-09 | 米纳瓦生物技术公司 | Muc1*抗体 |
| US20110195089A1 (en) | 2008-10-08 | 2011-08-11 | The Adminstrators Of The Tulane Educational Fund | Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens |
| KR20190122749A (ko) * | 2009-06-11 | 2019-10-30 | 미네르바 바이오테크놀로지 코포레이션 | 줄기세포 및 전구세포를 배양하는 방법 |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2768945B1 (en) | 2011-10-17 | 2022-01-05 | Minerva Biotechnologies Corporation | Media for stem cell proliferation and induction |
| BR112014020697B1 (pt) | 2012-02-24 | 2024-01-09 | Alteogen Inc | Anticorpo modificado compreendendo um motivo contendo cisteína na terminação do anticorpo, conjugado anticorpo-droga modificado compreendendo uma droga ligada ao anticorpo modificado e método de produção do mesmo |
| WO2013151665A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| AU2013295811A1 (en) * | 2012-07-24 | 2015-03-12 | Minerva Biotechnologies Corporation | NME variant species expression and suppression |
| AU2013302620B2 (en) * | 2012-08-14 | 2018-08-02 | Minerva Biotechnologies Corporation | Stem cell enhancing therapeutics |
| WO2014052693A2 (en) | 2012-09-29 | 2014-04-03 | The Trustees Of The University Of Pennsylvania | Veterinary composition and methods for non-surgical neutering and castration |
| US20160326263A1 (en) | 2013-02-20 | 2016-11-10 | Minerva Biotechnologies Corporation | NME Inhibitors and Methods of Using NME Inhibitors |
| IL307628A (en) * | 2013-02-20 | 2023-12-01 | Minerva Biotechnologies Corp | Nme inhibitors and methods of using nme inhibitors |
| EP3129476B1 (en) | 2014-04-07 | 2022-01-05 | Minerva Biotechnologies Corporation | Anti-nme antibody |
| JP6895890B2 (ja) | 2015-02-10 | 2021-06-30 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗ｍｕｃ１＊ 抗体 |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US11136399B2 (en) | 2016-07-14 | 2021-10-05 | Institute Of Biophysics, Chinese Academy Of Sciences | Type I interferon receptor antibody and use thereof |
| US20200165354A1 (en) | 2016-09-20 | 2020-05-28 | WuXi Biologics Ireland Limited | Novel Anti-PCSK9 Antibodies |
| EP3525804A4 (en) | 2016-10-11 | 2020-09-09 | Minerva Biotechnologies Corporation | HUMANIZED ANTI-MUC1 * ANTIBODIES AND USE OF THE CLIVING ENZYME |
| US20200390870A1 (en) | 2017-11-27 | 2020-12-17 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and direct use of cleavage enzyme |
| CN113727602B (zh) | 2019-02-04 | 2023-10-03 | 米纳瓦生物技术公司 | 抗nme抗体及治疗癌症或癌症转移的方法 |
| CA3181655A1 (en) | 2020-06-08 | 2021-12-16 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| KR20230028796A (ko) | 2020-06-26 | 2023-03-02 | 미네르바 바이오테크놀로지 코포레이션 | 항-nme 항체 및 암 또는 암 전이의 치료 방법 |
-
2015
- 2015-04-07 EP EP15776097.6A patent/EP3129476B1/en active Active
- 2015-04-07 CN CN201580030021.0A patent/CN106414726A/zh active Pending
- 2015-04-07 EP EP21217415.5A patent/EP4050103A1/en active Pending
- 2015-04-07 KR KR1020167030925A patent/KR102294483B1/ko active Active
- 2015-04-07 TW TW104111213A patent/TWI746420B/zh active
- 2015-04-07 CA CA2945162A patent/CA2945162A1/en active Pending
- 2015-04-07 SG SG11201608389RA patent/SG11201608389RA/en unknown
- 2015-04-07 WO PCT/US2015/024764 patent/WO2015157322A2/en not_active Ceased
- 2015-04-07 JP JP2016561611A patent/JP6401292B2/ja active Active
- 2015-04-07 AU AU2015243948A patent/AU2015243948B2/en active Active
- 2015-04-07 US US15/302,461 patent/US20170204196A1/en not_active Abandoned
- 2015-04-07 KR KR1020217026634A patent/KR20210107166A/ko not_active Withdrawn
- 2015-04-07 SG SG10201808867PA patent/SG10201808867PA/en unknown
-
2016
- 2016-10-06 IL IL248220A patent/IL248220A0/en unknown
-
2018
- 2018-08-24 US US16/111,894 patent/US11702483B2/en active Active
- 2018-08-24 US US16/111,862 patent/US20190031778A1/en not_active Abandoned
- 2018-09-05 JP JP2018165618A patent/JP6646118B2/ja active Active
-
2020
- 2020-01-08 JP JP2020001446A patent/JP7042854B2/ja active Active
-
2022
- 2022-03-07 IL IL291164A patent/IL291164A/en unknown
- 2022-03-15 JP JP2022040438A patent/JP2022095648A/ja active Pending
- 2022-04-12 US US17/719,302 patent/US12479928B2/en active Active
-
2024
- 2024-03-04 JP JP2024032381A patent/JP2024084747A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512825A5 (enExample) | ||
| JP2017504577A5 (enExample) | ||
| JP2019535763A5 (enExample) | ||
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| JP2016525551A5 (enExample) | ||
| MX2024013960A (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PH12014500089A1 (en) | Antibodies that bind to ox40 and their uses | |
| JP2020536109A5 (enExample) | ||
| JP2020524661A5 (enExample) | ||
| MX2009010120A (es) | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. | |
| WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
| JP2017522903A5 (enExample) | ||
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| JP2016527314A5 (enExample) | ||
| MX2019012869A (es) | Anticuerpos anti-sortilina y metodos para su uso. | |
| NZ597023A (en) | Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same | |
| JP2017536341A5 (enExample) | ||
| JP2016512214A5 (enExample) | ||
| JP2020507561A5 (enExample) | ||
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| RU2017105596A (ru) | Антитела к церамиду | |
| JP2021512159A5 (enExample) | ||
| PH12022551828A1 (en) | Multispecific antibodies, compositions comprising the same, and vectors and uses thereof | |
| RU2011143903A (ru) | Антитела к человеческому tweak и их применение | |
| EA202190235A1 (ru) | Антитела к cd33 и способы их применения |